Dr. Stephen J. Bales, a surgeon at the Washington Hospital Center in suburban Washington, D.C., is one of several specialists prescribing single-doses of a drug known as pnes.
The medication, which is administered once daily, is part of a broader treatment strategy to help patients with chronic pain get enough oxygen to breathe.
He and his colleagues have treated patients for more than 20 years, including a couple who were so heavily sedated they couldn’t speak, Bales said.
His patients, he said, have never had a history of PNS, and have been on pnes for more years than any other type of drug.
The drug is also being studied to help manage pain associated with nerve damage and infection, said Dr. David M. Taffel, director of pain medicine at Johns Hopkins University and an adviser to the National Institute on Drug Abuse.
Bals’ patients have a higher prevalence of the condition, Taffle said.
Bils treatment includes using an airway device, which he said is a noninvasive device that provides an air pump to assist the patient breathing.
He also recommends that patients take a single dose of pnes every other day.
The drugs, called COVID-19 vaccines, are not FDA approved, and doctors must take a prescription from a physician, Tafel said.
“There is no data that suggests that it is safe to give these drugs to these patients,” he said.
But patients may want to consider taking the drugs because the condition is so common in patients with the condition.
“The most common complaint that patients have is that they can’t breathe,” said Bals, a physician who practices in Washington, about an hour outside Washington.
“It is very difficult to get oxygen through the respiratory system, and they have no way to get it.”
Bals said he has treated hundreds of patients with COVID and the pnes drug.
He said he would prescribe the drug to patients with a history or physical ailment that made it difficult for them to breathe, including heart disease, arthritis and multiple sclerosis.
His colleagues have prescribed the drug twice a day, but Bals prefers to give it twice a week.
Bins said that while he has never seen a case of PTSD among his patients, the condition has been reported to other specialists in the medical field.
PNS is a rare condition that involves the development of abnormal breathing muscles.
It is more common than it should be, Taskle said, because most people who experience PNS develop the condition in childhood.
It may be triggered by other causes, such as stress, medication or environmental toxins, he added.
Patients with PTSDs often develop chronic pain, including from arthritis, a condition that is common in the older population.
Symptoms of POTS include severe pain, fever, chest pain, cough, trouble breathing, nausea and vomiting.
The condition usually goes away with medication and supportive care, but some patients also develop anxiety, depression and suicidal thoughts, said Taskel, an expert in chronic pain at the University of Virginia Medical Center in Charlottesville.
Pneumatic devices used to administer medications are often used to treat chronic pain.
The devices are used to relieve pressure on muscles, or to help a patient to breathe without having to hold the device in one hand.
Bels said he sees the use of pneumatics in treating patients with pnes because they allow the doctor to make a “positive difference.”
“The only time you are going to use it is if you have an extreme case, and it does not need to be done,” he explained.
Balse’s patients have been given doses of pmes twice a month, twice a year, twice weekly and monthly.
Doctors have given them for more time than they normally would have, but they have also been given them daily for months.
He believes it helps to use them to get patients through the pain, and to give them an opportunity to relax and take care of their health, he explained, adding that patients can learn how to take them off if they develop symptoms or trouble breathing.
The Drug Enforcement Administration has not approved pnes, but it is being studied for its potential as an anti-pain medication.
Pnes has been studied in other areas, including for cancer treatment, to see if it works.
The FDA is currently reviewing the research.
“We do know that the drug works as a painkiller, and there are other potential side effects that are related to the drug,” said Tafle, the Johns Hopkins professor.
He cautioned against prescribing pnes to people who may be vulnerable to the condition and have a history, such a history could be associated with other serious illnesses, including cancer.
Buses treatment has not been tested for safety or efficacy in patients who have PNS or cancer.
But Bales is concerned that prescribing the drug would increase the risk of an accidental overdose or overdose by causing